For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

B Capital, a global multi-stage investment firm, today announced that it has been selected as a registered venture capital firm under the Government of Japan’s Agency for Medical Research and ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

AI in pharma offers opportunities in clinical trial optimization, drug discovery enhancement, personalized healthcare, and ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company' or 'Jyong Biotech'), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...